- Legend Biotech USA, Inc. (Philadelphia, PA)
- …developing advanced cell therapies across a diverse array of technology platforms , including autologous and allogenic chimeric antigen receptor T-cell, T-cell ... receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide.Legend… more
- Genmab (NJ)
- …innovative and collaborative team has invented next-generation antibody technology platforms and harnessed translational, quantitative and data sciences, resulting ... in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …developing advanced cell therapies across a diverse array of technology platforms , including autologous and allogenic chimeric antigen receptor T-cell, T-cell ... receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide.Legend… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …developing advanced cell therapies across a diverse array of technology platforms , including autologous and allogenic chimeric antigen receptor T-cell, T-cell ... receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide.Legend… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …developing advanced cell therapies across a diverse array of technology platforms , including autologous and allogenic chimeric antigen receptor T-cell, T-cell ... receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide.Legend… more
- LiveRamp (New York, NY)
- …also lead our incident response efforts and the development of threat detection platforms . **You will:** + Implement threat detection logic across various security ... platforms , including SIEM, and other security platforms as needed. + Utilize threat modeling and threat-based thinking to construct and prioritize detection use… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …developing advanced cell therapies across a diverse array of technology platforms , including autologous and allogenic chimeric antigen receptor T-cell, T-cell ... receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide.Legend… more
- Formation Bio (New York, NY)
- …Formation Bio, founded in 2016 as TrialSpark Inc., has built technology platforms , processes, and capabilities to accelerate all aspects of drug development and ... clinical trials. Formation Bio partners, acquires, or in-licenses drugs from pharma companies, research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to bring new medicines to patients. The… more
- Formation Bio (New York, NY)
- …Formation Bio, founded in 2016 as TrialSpark Inc., has built technology platforms , processes, and capabilities to accelerate all aspects of drug development and ... clinical trials. Formation Bio partners, acquires, or in-licenses drugs from pharma companies, research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to bring new medicines to patients. The… more
- Genmab (NJ)
- …innovative and collaborative team has invented next-generation antibody technology platforms and harnessed translational, quantitative and data sciences, resulting ... in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other… more
